KALARIS THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
KALARIS THERAPEUTICS, INC. (KLRS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $5.05 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.71.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.61, a 56.09% decline year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $19.61, a 21.87% decline year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $25.10, a 31.79% decline year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $1.27, a 99.51% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $260.59, a 1503.63% increase from fiscal 2023.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $16.25, a 19.27% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $20.13, a 20.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.05 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $3.71 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $1.27 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $260.59 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $11.32 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $10.38 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $8.61 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $16.25 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $16.38 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $15.83 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $19.61 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $20.13 10-K · filed 2023-02-15 | |||
| 2022-09-30 | $23.34 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $24.32 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $25.10 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $25.31 10-K · filed 2022-02-10 | |||
| 2021-09-30 | $25.29 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $29.43 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $36.80 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $27.97 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |